Attached files
| file | filename |
|---|---|
| 10-Q - QUARTERLY REPORT - ORAMED PHARMACEUTICALS INC. | f10q0221_oramedpharmaceutica.htm |
| EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10q0221ex32-1_oramedpharma.htm |
| EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10q0221ex31-2_oramedpharma.htm |
| EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10q0221ex31-1_oramedpharma.htm |
| EX-10.1 - SECOND AMENDMENT, DATED FEBRUARY 8, 2021, TO EMPLOYMENT AGREEMENT, ENTERED INTO - ORAMED PHARMACEUTICALS INC. | f10q0221ex10-1_oramedpharma.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the quarterly report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-Q for the period ended February 28, 2021 as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Avraham Gabay, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: April 13, 2021 | /s/ Avraham Gabay |
Avraham Gabay, Chief Financial Officer |